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Background: We noticed that a hypothesis based on the effect of geomagnetic disturbances (GMD) has the ability
to explain special features of multiple sclerosis (MS). Areas around geomagnetic 60 degree latitude (GM60L)
experience the greatest amount of GMD. The easiest way to evaluate our hypothesis was to test the association of
MS prevalence (MSP) with angular distance to geomagnetic 60 degree latitude (AMAG60) and compare it with the
known association of MS with geographical latitude (GL). We did the same with angular distance to geographic 60
degree latitude (AGRAPH60) as a control.
Methods: English written papers with MSP keywords, done in Europe (EUR), North America (NA) or Australasia
(AUS) were retrieved from the PubMed. Geomagnetic coordinates were determined for each location and AMAG60
was calculated as absolute value of numerical difference between its geomagnetic latitude from GM60L. By an
ecological study with using meta-regression analyses, the relationship of MSP with GL, AMAG60 and AGRAPH60
were evaluated separately. MSP data were weighted by square root of number of prevalent cases. Models were
compared by their adjusted R square (AR2) and standard error of estimate (SEE).
Results: 111 MSP data were entered in the study. In each continent, AMAG60 had the best correlation with MSP,
the largest AR2 (0.47, 0.42 and 0.84 for EUR, NA and AUS, respectively) and the least SEE. Merging both hemispheres
data, AMAG60 explained 56% of MSP variations with the least SEE (R = 0.75, AR2 = 0.56, SEE = 57), while GL explained
17% (R = 0.41, AR2 = 0.17, SEE = 78.5) and AGRAPH60 explained 12% of that variations with the highest SEE (R = 0.35,
AR2 = 0.12, SEE = 80.5).
Conclusions: Our results confirmed that AMAG60 is the best describer of MSP variations and has the strongest
association with MSP distribution. They clarified that the well-known latitudinal gradient of MSP may be actually a
gradient related to GM60L. Moreover, the location of GM60L can elucidate why MSP has parabolic and linear
gradient in the north and south hemisphere, respectively. This preliminary evaluation supported that GMD can be
the mysterious environmental risk factor for MS. We believe that this hypothesis deserves to be considered for
further validation studies.
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In spite of many efforts since the time of rendering Mul-
tiple Sclerosis (MS) as a disease, its etiology remains un-
clear. Although it is accepted that auto-reactive
lymphocytes play essential role in MS, the cause of this
auto-reactivity and its relapsing-remitting course are un-
known [1]. Up to now, genetic studies could not deter-
mine specific genes as the cause of MS and studies on
monozygotic twins demonstrated that the role of genes
in the susceptibility to MS does not exceed 30% [2].
Researchers always indicate that the major role in MS
pathogenesis is attributed to the effect of environmental
factor(s) on the basis of a genetical susceptibility [1].
Specific epidemiological features of MS, such as signifi-
cant latitudinal gradient of prevalence, the effect of mi-
gration, and the effect of month of birth on alteration of
the risk of MS, all indicate to the presence of an envir-
onmental factor that should be strongly related to time,
location and geophysical features. It is repeatedly tested
and accepted that MS prevalence has a latitudinal gradi-
ent and its prevalence has a positive relation to the dis-
tance from the equator [3]. Based on this fact, all efforts
have been toward finding a hypothesis that explains MS
etiology by an environmental factor that change in
agreement with this feature. According to this opinion,
the recent hypothesis that tries to explain MS prevalence
distribution and etiology by the possible immunomodu-
latory effect of vitamin D [4] seems to be reasonable, be-
cause of the common belief that production of vitamin
D is related to the amount of received solar ultra-violet
radiation and expected to have a latitudinal gradient.
But there is an important feature in MS prevalence
that seems to be neglected by researchers who seek the
key of MS explanation by vitamin D hypothesis (VDH).
This fact is that MS prevalence gradient is different in
north and south hemispheres and is not linear every-
where. Based on epidemiological data, this gradient is
parabolic in north hemisphere, while seems linear in the
south hemisphere. This feature was identified from the
first reports of this gradient [5] up to the most recent
study [3].
Regarding to this issue and other epidemiological fea-
tures of MS, we tried to investigate if there is another
environmental factor that give a potentially better ex-
planation about MS distribution. To achieve this aim,
we reviewed possible environmental factors from space
to ground level and checked whether their effects on MS
epidemiology were studied or not. Interestingly, many
factors including extra-terrestrial phenomena such as
cosmic ray to solar irradiation, and terrestrial factors
such as temperature, humidity, sanitation and steel, food
or energy consumption have been investigated [4,6-9].
Considering this list, we found that the possible effect
of geomagnetic disturbances (GMD), a phenomenonrelated to interactions of space-weather situations and
magnetosphere, on this disease was not concerned up to
now. It is not surprising because the concept of space-
weather is relatively new and the main researches about
this phenomenon have been done in recent four decades
[10]. Moreover, as geomagnetic field (GMF) and its dis-
turbances are categorized as very low magnetic field
(VLMF) without thermal and ionizing effect, their effects
on physiological and pathophysiological issues, in com-
parison to other environmental factors, have generally
been neglected by most biologists [11].
After comparing the various features of GMD and
evaluating various evidences of effects of this phenomenon
on living beings, we found that a hypothesis based on
GMD has the ability to give reasonable answer to several
questions about MS.
Because neuroscientists and neuroepidemiologists are
among the main target population of this hypothesis and
they may be unfamiliar with details of space-weather
and physics of GMD, a brief review about their features
has put the first.
Basics of Space-weather and GMD
Space around our planet is not empty and the Earth is
immersed in the solar energetic charged particles.
Space-weather defined as the conditions in space that
affect Earth, consequences of flowing ionized particle of
the solar wind against GMF [10]. However GMF acts
like a shield and deflect most of the solar charged parti-
cles, it is also impressed and altered by solar wind [10].
These GMF alterations are called GMD. GMF has differ-
ent strength and direction in different areas of the Earth.
Its magnitudes vary from ~35000 nano Tesla (nT) in
equator to ~70000 nT in the magnetic poles [11]. Sev-
eral periodic variations have also been shown in GMF
that most of them are related to various solar cycles, es-
pecially 11 year cycle, and others are related to Earth’s
rotation and situation in its orbit [11].
For quantifying GMD, several indices such as Planet-
ary K index (Kp) and Planetary A index (Ap) were
defined. Kp is a quasi-logarithmic scale for summarizing
global geomagnetic activity in the range 0–9, which 1
and 2 being quiet state, 3 and 4 indicating unsettled and
5 or more illustrate geomagnetic storm [12]. Like geo-
graphical coordinates that are defined among Earth’s
geographical poles, there are geomagnetic coordinates
that are defined on the basis of Earth’s magnetic dipole.
Regarding the fact that the location of magnetic dipoles
are different from geographical ones and the fact that
magnetic dipoles are not located completely antipodal
and their locations change slowly, geomagnetic latitude
and longitude of every location are completely different
from its geographical coordinates (Figure 1). It is a very
important note because the rate of magnetic field
Figure 1 Geomagnetic coordinates in comparison to geographic coordinates. Note: curve lines indicate geomagnetic latitudes and longitudes.
Straight lines illustrate geographic latitudes and longitudes. Reproduced by the kind permission of National Geophysical Data Center [13].
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with its location in the geomagnetic coordinate.
Solar activities and inter-planetary magnetic field provoke
GMD by causing two different but related phenomena, in-
cluding magnetospheric substorms and geomagnetic
storms. Magnetospheric substorms occur frequently and
disturb high latitudes of both hemispheres within ring
shaped area known as auroral oval, and can cause up to
2000 nT GMD for few hours [14]. Auroral oval lies at geo-
magnetic latitude ~63° to ~75° of both hemispheres in
quiet geomagnetic situations. Equatorward boundary of
auroral ovals expand during unsettled situations, i.e. Kp =
3 and 4, to geomagnetic ~60° and ~58° latitude, respect-
ively [15].
In the other hand, geomagnetic storms are less fre-
quent but global phenomena and have impact on low
and mid-latitudes, as well as high latitudes. They cause
up to 400 nT GMD and last for few days [14]. During
their occurrence and relative to the degree of GMD, Kp
index varies among 5 to 9. It should be noted that dur-
ing a geomagnetic storm, substorms also occur and the
location of the equatorward boundary of auroral ovals
depend on the severity of disturbances. For example,
they may expand to geomagnetic ~48° latitude in Kp= 9
situation [15].
The Hypothesis
A good hypothesis about MS should be able to give an
acceptable explanation about its pathophysiology, behav-
ior and special distribution.In recent decades, because of vast development of
wireless communication devices, concerns about the ef-
fect of VLMF on health have raised and many studies
had been conducted toward them. Nevertheless, the
magnitude and frequency of wireless appliance electro-
magnetic fields are different from GMF and therefore,
finding studies about the effect of magnetic field with
same characteristics as GMF was very difficult. However
such studies were sparse, in this section we tried to de-
scribe that GMD hypothesis has the potential ability to
explain some aspects of MS pathophysiology and
behavior.
Even with its low magnitude, GMF affects living
beings. It was shown that in a weakened GMF situation,
by using shielded chamber, hormonal disturbances occur
in animal models, especially in the blood level of epi-
nephrine, histamine and serotonin. Plants also are influ-
enced by it and weakened GMF can cause changes in
root meristems and subcellular structures like mitochon-
dria [11]. We know that some species sense GMF, prob-
ably by presence of magnetites, i.e. ferromagnetic
particles in their central nervous system (CNS), and use
it for orientation and migration [11]. It was shown that
human brain also contains magnetites [16] and it was
proposed that observed increases in stress hormones,
heart rate, and the amount of myocardial infarctions
during geomagnetic storms may induced by causing an
adaptive stress reaction through the effect of GMD on
brain magnetosomes [17,18]. Accordingly, histochemical
finding about the presence of considerable iron deposits
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technics about increased iron deposits in subcortical
gray matters of MS patients [20], in addition to some
results about greater incidence of cardiovascular diseases
among MS patients [21], all may be regarded as indirect
clues of a probable relation among the effects of GMD
on brain magnetosomes and pathogenesis of MS. How-
ever, it should be reminded that we don’t know how
amount of these iron deposits are in the form of
magnetite.
Regardless of these facts, any hypothesis about MS
should have the ability to describe why and how adaptive
immune system is activated in a relapsing-remitting
manner against myelin that is an immune privileged
component [22,23]. CNS is regarded as the most sensi-
tive organ to GMF and some studies demonstrated that
CNS reactions to magnetic field resulted mainly from
magnetic field effects on glial cells and especially blood
brain barrier [11] that are the main participants in MS
pathophysiology.
However migration of myelin-specific T cells from sys-
temic circulation to CNS has a great role in MS, their
sole presence is not more regarded as the main cause of
MS; because their presence was also demonstrated in
healthy individuals. Rather, what is considered to be im-
portant is the activation state of these cells [22]. A naïve
T cell, primarily for transforming to effector or memory
T cell, needs two activator signals: peptide/major histo-
compatibility complex (MHC) and co-stimulatory signal.
Then this effector cell for activation needs only the
signal one [22]. These signals affect membrane signalFigure 2 Cycle average of number of days that has been spent in eac
average was calculated based on daily Ap index, but because the location
interpreted as equal amounts of Kp. Constructed based on the Kp and Ap
by the kind permission of NOAA.transduction systems and by starting a cascade of reac-
tions and production of messenger molecules, finally
change gene expression and cell differentiation. After all,
adhesion and entering to the CNS are necessary for acti-
vated T cells to be capable of exertion an inflammatory
response [22,24].
There are evidences that adaptive immune system can
be affected by VLMF. Magnetic field as low as GMF can
significantly change lymphocyte Ca2+ uptake [25]. In
addition, through three proposed mechanisms, GMF can
change leukocyte behavior, activation and adhesion by
inducing the membrane-mediated signal transduction
cascades, like the time that a ligand-receptor interaction
activates the cell [24-27]. Those mechanisms include
changes of ion flux, especially Ca2+ across cell mem-
brane, cyclotron resonance and dissociation of protein-
ion complex by changing quantum states of ions in their
structures in the membrane proteins [24]. There are also
evidences that magnetic fields can enhance release of re-
active oxygen species by T cells and macrophages [26].
Regarding these facts, we can see that GMD has the po-
tential features to provide the essential neuroimmunolo-
gical context of MS. Therefore, as the core of our
hypothesis we assumed that vulnerable individuals,
based on their genetical susceptibility of cell response to
magnetic fields, would suffer from MS attacks in the
geographical locations and time periods that GMD
matches with the sensitivity of their adaptive cell im-
munity and lasts enough to stimulate various elements
of this system for entering to CNS and activating with-
out the presence of a co-stimulatory signal. Thish space-weather situation during solar cycle 17 to 23. Note: Cycle
of auroral oval can be determined by Kp, measurements were
data from National Oceanic and Atmospheric Association (NOAA) [12]
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ing remitting nature.Testing by an ecological study
After structuring GMD hypothesis, we planned to test it.
We explained in previous sections that auroral oval
boundaries are areas that more frequently and with the
greatest magnitude are affected by GMD. As is obvious
in Figure 2, most of disturbed days are elapsed in Kp= 3
situation in each solar cycle. In such a situation, the
equatorward border of auroral oval locates upon geo-
magnetic ~60 latitude in both northern and southern
hemispheres [15]. This means that all living beings in
these areas experience more geomagnetic disturbances
in comparison to other parts.
Regarding to these facts, the easiest but indirect way
to evaluate the possible association of MS with GMD
seemed to check the correlation of disease prevalence
with angular distance to geomagnetic 60° latitude
(AMAG60) as the border of the most affected area by
space-weather through an ecological study and to com-
pare it with the well-known association of MS with geo-
graphical latitudes, i.e. the angular distance from
geographical equator. Therefore, we designed an eco-
logical study with using meta-regression analysis on the
prevalence studies of MS to check such a correlation. To
have controls, we considered to check likewise correla-
tions with angular distance to geographical 60 latitude
(AGRAPH60) and geomagnetic latitudes.Methods
Search strategy and selection criteria
As the most accurate MS prevalence studies have been
done in western countries, we retrieved English written
papers with the keywords of “prevalence” or “epidemi-
ology” and “multiple sclerosis” in the title, published
since 1980 up to the 2010, from the PubMed that were
done in western countries (Additional file 1:Appendix 1.
Search strategy ). In addition, authors combined articles
from their archive to results retrieved from the PubMed.
Our definition of western countries includes countries of
western European and other states regional group of
United Nation [28]. MS prevalence data including the
location of study, the year of estimation of prevalence,
the number of prevalent cases and calculated MS preva-
lence per 100000 were extracted from included studies.
Only MS prevalence data were entered in the analyses
that their original study used an approved MS diagnostic
criterion with more than 20 prevalent cases and clearly
indicated the number of prevalent cases. For studies that
used patients’ self-report of having MS, according to
their neurologists’ diagnosis, we accepted the data only
if the study population were such large, i.e. at least onemillion or more, that choosing self-report method
seemed practically inevitable and reasonable.
In the cases that several studies reported prevalence in
a same location, only the latest report was entered.
For each entry, the geographical latitude and longitude
were retrieved from coordinate index list of a geograph-
ical textbook [29]. In the cases that the study area
involves population of a political region, i.e. whole coun-
try, a state, a province or multiple neighbor cities, we
considered the coordinates that resemble the point of
symmetry of geometrical figure of that political region.
By using an online calculator based on the international
geomagnetic reference field data source [30], geomag-
netic coordinates were calculated from geographical
coordinates for each location in the year that MS preva-
lence was reported or in the nearest available time to
that year. For example, geographical latitude of London
is 51.5° N, whereas its geomagnetic latitude in 1985, the
nearest time to the last MS prevalence report, was
recorded as 53.66° N.
For any location, AMAG60 was determined by calcu-
lation of absolute value of numerical difference between
its geomagnetic latitude from geomagnetic 60° latitude
(GM60L). A same manner was done for calculation of
AGRAPH60.
Analyses
By using meta-regression analysis, the association of MS
prevalence with geographical latitude, geomagnetic lati-
tude, AMAG60 and AGRAPH60 were evaluated separ-
ately. In each analysis, we regarded MS prevalence of
populations as dependent variables and geographical or
geomagnetic related variables as independent variables.
Logarithmic and linear models were tested for each vari-
able and the best fitted model was selected for final
inter-variable comparison. Models were compared by
their adjusted R2 (coefficient of determination) and
standard error of estimate (SEE).
In all meta-regression analyses, prevalence data were
weighted with the square root of the number of preva-
lent cases. In all tests, a p-value lesser than 0.05 was
regarded as significant. We did analyses by using IBM
SPSS statistics (IBMW, New York, USA).
Results
Among 377 retrieved and reviewed abstracts, full texts
of 110 selected articles were read and according to our
inclusion criteria, finally 87 papers from 24 western
countries with 111 MS prevalence data were entered in
the analyses. Of them, origin of 64 articles were from
our search in the PubMed and 23 articles from authors'
archive (Figure 3) (Table 1).
Of 111 entered MS prevalence data, 19 data were from
Australasia, including Australia and New Zealand, 77
Figure 3 Flow diagram of study selection.
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plotted MS prevalence estimate data against geographic
and geomagnetic latitudes, AGRAPH60 and AMAG60,
separated by continents. Results were summarized in
Table 2 and Figure 4 (Additional file 2: Appendix 2,
Additional file 3: Appendix 3, Additional file 4: Appendix
4, Additional file 5: Appendix 5 and Additional file 6:
Appendix 6 include high resolution formats of Figure 4
separated by rows ). All latitudinal variables of study
showed significant statistical correlation with MS preva-
lence. In each continent, geomagnetic latitude showed
approximately identical or mildly better relationship with
MS prevalence in comparison to geographic latitude.
Their models had nearly equal adjusted R2 (AR2) and
SEE. Model based on AMAG60 had always the best asso-
ciation with MS prevalence with the greatest AR2 and the
least SEE. AGRAPH60 model showed the weakest associ-
ation with MS prevalence in each continent, with the
least AR2 and the greatest SEE.
When we merged the data of Europe and North
America to check the ability of models to explain MS
prevalence variations in north hemisphere, AMAG60
was the best model that could describe 50% of variations
in MS prevalence in a logarithmic manner, with a very
strong correlation and the least SEE. The relationship of
geographic latitude and AGRAPH60 was weak and theycould describe only 7% and 4% of MS prevalence vari-
ation of north hemisphere, respectively.
Merging the data of both hemispheres, models based
on AGRAPH60, geographic latitude and geomagnetic
latitude could explain 12%, 17% and 40% of variations in
MS prevalence, respectively. Whereas, AMAG60 illu-
strated very strong association with MS prevalence and
could describe 56% of its variations with the least SEE.
Discussion
All latitudinal variables of study showed significant stat-
istical association with MS prevalence. It was expected
to some extent, due to the latitudinal dependent nature
of MS. Our analyses confirmed that in each continent,
the association of MS prevalence with geomagnetic lati-
tude is equal or mildly better than geographic latitude. It
should be noted that attention to the association of MS
with geomagnetic coordinates has precedent. About
50 years ago Barlow noticed that geomagnetic latitude
could give a better explanation about MS prevalence and
some of its special distribution features, such as
the cause of lower prevalence of MS in Japan in com-
parison to other location with identical geographical
latitude [6]. However he paid attention to an important
fact, unfortunately he never realized the critical role
of geomagnetic ~60° latitude and possible role of
Table 1 Prevalence estimate data that were selected and entered for meta-regression analysis













Alberta 2004 11562 357 52 58.9 1.1 8 Warren et al. [31] †
Atlantic 2000 16032 350 49.3 59.3 0.7 10.7 Beck et al. [32] †
British Colombia 1982 4620 131 54 59.18 0.82 6 Sweeney et al. [33]
London (Ontario) 1983 190 94 42.59 53.21 6.79 17.41 Hader et al. [34]
Ontario 2000 33529 230 51 60.9 0.9 9 Beck et al. [32] †
Québec 2000 20551 180 52 62.27 2.27 8 Beck et al. [32] †
Saskatoon 2005 537 298 52.07 59.84 0.16 7.93 Hader and Yee [35]
Westlock 1991 23 200 54.09 61.11 1.11 5.91 Warren and Warren [36]
United States of America
Colorado 1982 274 84 39.3 47.98 12.02 20.7 Nelson et al. [37]
Key West 1985 22 70 24.33 35 25 35.67 Helmick et al. [38]
Sugarcreek & Independence
(Missouri)
2010 106 86 41.24 50.93 9.07 18.76 Noonan et al. [39]
Lorain county
(Ohio)
2010 320 109 41.22 50.89 9.11 18.78 Noonan et al. [39]
Olmsted 2000 218 177 41.24 51.32 8.68 18.76 Mayr et al. [40]
Rochester 1984 102 173 44.02 53.24 6.76 15.98 Wynn et al. [41]
Texas 2000 182 42 31.3 40.26 19.74 28.7 Noonan et al. [39]
Australasia
Australia
Canberra 1996 155 49 35.16 42.74 17.26 24.84 Simmons et al. [42]
Newcastle 1996 79 59 32.55 39.86 20.14 27.45 Barnett et al. [43]
New South Wales 1981 1907 37 33 41.5 18.5 27 McLeod et al. [44]
South Australia 1981 378 28 30 39.77 20.23 30 McLeod et al. [44]
New Zealand 2010 2917 73.1 Taylor et al. [45] {
Auckland 2006 732 59 36.5 39.8 20.2 23.5 Taylor et al. [46]
Bay of plenty 2006 132 50 38.3 41.12 18.88 21.7 Taylor et al. [46]
Canterbury 2006 557 103 44.2 47.85 12.15 15.8 Taylor et al. [46]
Gisborne 2006 20 46.7 38.4 41.05 18.95 21.6 Taylor et al. [46]
Hawke Bay 2006 82 54.3 39 41.8 18.2 21 Taylor et al. [46]
Manawatu-
Wanganui
2006 120 54 39.7 42.74 17.26 20.3 Taylor et al. [46]
Marlborough 2006 42 86.8 41.4 44.75 15.25 18.6 Taylor et al. [46]
Nelson-Tasman 2006 75 77.7 41.17 44.6 15.4 18.83 Taylor et al. [46]
Northland 2006 82 50.8 35.5 38.9 21.1 24.5 Taylor et al. [46]
Otago 2006 234 119.3 44.45 48.45 11.55 15.55 Taylor et al. [46]
Southland 2006 148 134.6 45.5 49.74 10.26 14.5 Taylor et al. [46]
Taranaki 2006 72 66.8 39.2 42.46 17.54 20.8 Taylor et al. [46]
Waikato 2006 177 46.4 37.7 40.8 19.2 22.3 Taylor et al. [46]
Wellington 2006 383 86.2 41.18 44.36 15.64 18.82 Taylor et al. [46]
Western Europe
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Table 1 Prevalence estimate data that were selected and entered for meta-regression analysis (Continued)
Austria 2000 3420 98 47.2 46.94 13.06 12.8 Baumhackl
et al. [47]
Belgium
Flandern 1991 220 88 51 52.54 7.46 9 van Ooteghem
et al. [48]
Denmark 2005 9377 154 56 55.95 4.05 4 Bentzen et al. [49]
England
Cambridgshire 1993 347 119 52.2 54.16 5.84 7.8 Robertson et al. [50]
Devon 2001 409 118 50.45 53.09 6.91 9.55 Fox et al. [51]
East Angelia 1990 374 112 52.3 54.49 5.51 7.7 Mumford et al. [52]
Guernsey 1993 53 95 49.28 51.81 8.19 10.72 Sharpe et al. [53]
Jersey 1993 95 120 49.2 51.69 8.31 10.8 Sharpe et al. [53]
Leeds 1996 712 84 53.5 55.67 4.33 6.5 Ford et al. [54]




1995 449 118 51.5 53.65 6.35 8.5 Robertson et al. [56]
Rochdale 1989 200 96 53.38 55.77 4.23 6.62 Shepherd and
Summers [57]
Southampton 1987 384 92 50.55 52.97 7.03 9.45 Roberts et al. [58]
Suffolk 1988 58 153 52.18 54.05 5.95 7.82 Lockyer [59]
Sussex 1991 665 111 51.03 53.14 6.86 8.97 Rice-Oxley et al. [60]
Finland
Central Finland 2000 277 105 62.5 59.31 0.69 2.5 Sarasoja et al. [61]
Sienajoki 1993 398 186 62.45 59.78 0.22 2.45 Sumelahti et al. [62]
Ussima 1993 1380 92 60.12 57.3 2.7 0.12 Sumelahti et al. [62]
Vaasa 1993 199 108 63.09 60.53 0.53 3.09 Sumelahti et al. [62]
France
Lorraine 2004 2718 120 49 49.93 10.07 11 Debouverie et al. [63]
Germany




1986 222 83 52.63 52.84 7.16 7.37 Poser et al. [65]
Southern Hesse 1980 324 52 49.8 50.28 9.72 10.2 Lauer et al. [66]
Iceland 1989 252 100 65 62.9 2.9 5 Benedikz et al. [67]
Ireland
Donegal 2001 240 185 54.5 57.77 2.23 5.5 McGuigan et al. [68]
Wexford 2001 126 121 52.2 55.28 4.72 7.8 McGuigan et al. [68]
Italy
Alghero 1980 44 59 40.34 44.5 15.5 19.66 Rosati et al. [69]
Aosta 1989 36 39 45.44 46.41 13.59 14.56 Sironi et al. [70]
Bagheria 1994 25 49 38.05 38.07 21.93 21.95 Salemi et al. [71]
Barbagia 1981 32 78 40.56 41.3 18.7 19.44 Granieri et al. [72]
Caltanissetta 2002 101 166 37.48 37.37 22.63 22.52 Grimaldi et al. [73]
Catania 1995 195 58 37.5 37.21 22.79 22.5 Nicoletti et al. [74]
Enna 1995 34 120 37.34 37.22 22.78 22.66 Grimaldi et al. [75]
Ferrara 2003 423 121 44.53 44.9 15.1 15.47 Granieri et al. [76]
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Table 1 Prevalence estimate data that were selected and entered for meta-regression analysis (Continued)
Genoa 1997 857 85 44.25 44.99 15.01 15.75 Solaro et al. [77]
L’Aquila city 1984 22 34 42 42.2 17.8 17.78 Salerni et al. [78]
L’Aquila Province 1996 158 56 42.22 42.13 17.87 17.78 Totaro et al. [79]
Modena 1990 404 39 44.4 44.73 15.27 15.6 Guidetti et al. [80]
Monreale 2000 21 71 38.05 38.08 21.92 21.95 Ragonese et al. [81]
North Western
Sardinia
1991 276 103 40.12 40.93 19.07 19.88 Rosati et al. [82]
Padova 1999 667 81 45.4 45.44 14.56 14.6 Ranzato et al. [83]
Salerno 2005 186 72 40.67 40.31 19.69 19.33 Iuliano and
Napoletano [84]
Nuoro 1993 394 144 40.19 40.96 19.04 19.81 Casetta et al. [85]
Sassari 1997 686 144 40.44 41.31 18.69 19.56 Pugliatti et al. [86]
Malta 1999 63 13 35.5 35.39 24.61 24.5 Dean et al. [87]
Northern Ireland 2004 370 200 54.4 57.28 2.72 5.6 Gray et al. [88]
Norway
Hordaland 2003 666 151 60.15 60.53 0.53 0.15 Grytten et al. [89]
Møre og Romsdal 1985 159 75 62.3 62.42 2.42 2.3 Midgard et al. [90]
Nord Trondelag 2000 208 164 64.43 63.53 3.53 4.43 Dahl et al. [91]
Oslo 2005 759 170 59.56 59.3 0.7 0.44 Smestad et al. [92]
Troms and Finmark 1993 184 73 69.4 66.8 6.8 9.4 Gronlie et al. [93]
Vestfold 1983 163 86 59.25 58.8 1.2 0.75 Edland et al. [94]
Portugal
Santarem 1998 29 46 39.14 43 17 20.86 De Sa et al. [95]
San Marino (Republic of) 2005 50 167 43.56 43.56 16.44 16.44 Granieri et al. [96]
Scotland
Glasgow 2002 245 145 55.53 58.06 1.94 4.47 Murray et al. [97]
Lothian and Border 1995 1613 203 55.55 57.93 2.07 4.45 Rothwell and
Charlton [98]
Orkney 1983 37 193 59 61.29 1.29 1 Cook et al. [99]
Shetland 1986 40 184 60.3 62.18 2.18 0.3 Cook et al. [100]
Tayside 1996 727 184 55.87 58.41 1.59 4.13 Forbes et al. [101]
Spain
Alcoy 1988 23 17 38.42 40.92 19.08 21.58 Matias-Guiu
et al. [102]
Bajo Aragon 2003 44 75 41 43.43 16.57 19 Modrego and
Pina [103]
Canary Islands 1998 34 42 28 33.26 26.74 32 Hernandez [104]
Gijon 1994 22 65 43.32 46.62 13.38 16.68 Uria et al. [105]
Las Palmas 2002 64 61 28.6 33.83 26.17 31.4 Aladro et al. [106]
Menorca
(Balearic Islands)
1996 46 69 40 41.68 18.32 20 Casquero et al. [107]
Mostoles 1998 85 43 40.19 43.17 16.83 19.81 Benito-Leon et al. [108]
Northern Calatayud, 1995 34 58 41.21 43.84 16.16 18.79 Pina et al. [109]
Osona 1991 42 58 41.7 43.78 16.22 18.3 Bufill et al. [110]
Santiago de
Compostela
2003 71 79 42.53 46.18 13.82 17.47 Ares et al. [111]
Teruel 1996 46 32 40.21 42.82 17.18 19.79 Modrego Pardo
et al. [112]
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Table 1 Prevalence estimate data that were selected and entered for meta-regression analysis (Continued)
Valladolid 1997 54 58 41.39 44.57 15.43 18.61 Tola et al. [113]
Sweden 2008 17485 189 62 60.7 0.7 2 Ahlgren et al. [114]
Varmland 2002 580 170 59.48 58.69 1.31 0.52 Bostrom et al. [115]
Vasterbotten 1997 399 154 64.36 61.98 1.98 4.36 Sundstrom et al. [116]
Switzerland
Berne 1986 1016 110 46.57 47.53 12.47 13.43 Beer and
Kesselring [117]
Wales
South Glamorgan 1985 381 101 51.3 54.08 5.92 8.7 Swingler and
Compston [118]
South-East 2005 620 146 51.3 53.79 6.21 8.7 Hirst et al. [119]
N. Patients: Number of patients; GeoLat: Geographic latitude; GeoMag: Geomagnetic latitude; AMAG60: Angular distance to geomagnetic 60 latitude; AGRAPH60:
Angular distance to geographic 60 latitude.
† Studies that did not use a determined MS diagnostic criteria.
{ It was the latest report of MS prevalence in New Zealand (the entire country) that we found in the PubMed. But we found that their study result of prevalence
in each region of that country was published previously by MS society of New Zealand [46]. We entered the latter study [46] results in our analyses.
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of MS with geomagnetic latitude is originated from
cosmic-ray related production of radioactive atoms in at-
mosphere and their radiation effects [6]. Nevertheless
his opinion is very close to ours in the basic epidemio-
logical aspect, but our hypothesis and its descriptions
about MS pathogenesis and special features are com-
pletely different from Barlow’s final assumptions. As his
hypothesis about mutations due to radioactive effects of
cosmic rays could not explain MS pathophysiology and
behavior, the whole fact was neglected.
Our results indicated that in each continent, AMAG60
can give the best explanation about the variation of MS
prevalence. However, result of Australasia, including
Australia and New Zealand, was different from other
continents and all latitudinal variables illustrated very
strong association with MS distribution. They identically
could describe about 80% of variation of MS prevalence.
We regarded this as another confirmation for the effect
of AMAG60. As is obvious in Figure 1, Australasia is
located below geomagnetic ~60 latitude. Therefore, it
seems rationale that MS distribution shows a linear gra-
dient toward this critical line. This very linear arrange-
ment causes that geomagnetic and geographic latitudeTable 2 Coefficients of regression models
Europe North America North
R AR2 SEE R AR2 SEE R
AMAG60 0.69 0.47 33.8 0.65 0.42 69.85 0.71
GeoLat 0.58 0.34 37.93 0.40 0.16 84.36 0.27
GeoMag 0.60 0.36 37.17 0.40 0.16 84.36 0.57
AGRAPH60 0.42 0.18 42.27 0.21 0.05 89.85 0.19
R: Coefficient of correlation; AR2: Adjusted R2 (coefficient of determination); SEE: Sta
latitude; AGRAPH60: Angular distance to geographic 60 latitude; GeoLat: Geographi
† Australasia is a region that geopolitically comprises Australia and New Zealand.are able to explain variation of MS prevalence like
AMAG60. Geographic 60° latitude is also located be-
yond Australasia. Due to this reason, AGRAPH60 could
describe 84% of MS prevalence in this continent.
Merging the data of continents, especially in north
hemisphere, we found that AMAG60 can give the best
explanation about MS prevalence throughout the world
in comparison to other latitudinal variables. We regard
this advantage of AMAG60 as strong evidence that the
mysterious environmental risk factor for MS should be
correlated to this line more than other geographical fac-
tors. We mentioned in introduction that Earth’s surface
is subject to experience magnetic field disturbances up
to about 2000 nT under the auroral oval area because of
substorms. GM60L is the line that usually represents the
border of this oval in the most frequent disturbed situ-
ation, i.e. Kp = 3 situation. Therefore, considering the
supportive results of our meta-regression analyses, we
suppose that GMD can be the best candidate to be the
mysterious environmental risk factor for MS.
Beyond of being statistically associated to MS preva-
lence distribution, we believe that GMD hypothesis has
the ability to describe other important features of MS.
As the core of our hypothesis, we illuminated how GMDHemisphere Australasia† Both hemispheres
AR2 SEE R AR2 SEE R AR2 SEE
0.50 60 0.92 0.84 11.92 0.75 0.56 57.07
0.07 82 0.89 0.79 13.67 0.41 0.17 78.48
0.33 70 0.91 0.83 12.41 0.63 0.40 66.50
0.04 83 0.92 0.84 11.96 0.35 0.12 80.55
ndard error of estimates; AMAG60: Angular distance to geomagnetic 60
c latitude; GeoMag: Geomagnetic latitude.
Figure 4 MS Prevalence estimates by AMAG60, geographical latitude, geomagnetic latitude and AGARPH60. AMAG60: Angular distance
to geomagnetic 60° latitude; AGRAPH60: Angular distance to geographic 60° latitude; N. America: North America; North hemis: North hemisphere;
Both hemis: Both hemispheres. † Australasia comprises Australia and New Zealand. Dotted lines indicate line of regression.
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MS pathophysiology at molecular and cellular level. In
the following paragraphs, the ability of GMD to explain
other features of MS will be discussed.
MS prevalence in hemispheres
Parabolic gradient of MS prevalence in north hemi-
sphere and linear gradient in the south hemisphere can
be explained easily by GMD. As is obvious in Figure 1,
there are many inhabitant areas under and beyond
GM60L in the Europe and North America, while there
are not any inhabitant lands beyond this line in the
south hemisphere. If an important environmental factor
for MS is related to this line, it would be reasonable that
the disease shows parabolic and linear distribution in
north and south hemisphere, respectively.
Worldwide MS incidence and prevalence trend
When MS was framed by Charcot in mid-19th century,
it was considered as a rare disease and a subject for case
report [7]. During 20th century, MS incidence and ad-
mission grew very fast. This change was interpreted by
some researchers as “an epidemic of recognition rather
than the effect of altered biological factors” [7]. But from
1930s, an increase of MS incidence was reported initially
from high latitudes in north hemisphere like Iceland that
became notable from 1945 to 1954 [120]. Simultan-
eously, an identical trend of changes was reported from
South Africa in south hemisphere [121]. Then, remark-
able increase of MS incidence and prevalence wereFigure 5 Solar cycles and sunspot numbers. Note: number in the stars
permission of National Geophysical Data Center [125].reported from various locations such as Denmark, Faroe
Islands, Norway and Australia after 1960 [44,120].
Afterwards, however higher latitudes experienced a de-
creasing trend of incidence for a short period after
1965–70 [120,122], increasing incidence and prevalence
was reported from Scotland, United Kingdom and
Netherlands. Such a course of events could not be
explained by survival changes or case ascertainment
issues easily [120].
Very interestingly, mentioned course of MS prevalence
and incidence can be explained by GMD. Fortunately,
solar activity has been observed by means of regular
recording of sunspot numbers since 1700 [123]. Sunspot
numbers are correlated with solar cycles, solar magnetic
activity and hence with the frequency and strength of
GMD. Recently, Solanki et al. reconstructed sunspot
numbers for the past 11,400 years. Their results illu-
strated an increasing and longstanding exceptional solar
magnetic activity since 70 years ago that is unprece-
dented during past 8000 years [123]. Long-term analysis
of recorded GMF activities revealed that GMDs have fol-
lowed solar activity changes and have been increased, a
phenomenon that is known as “centennial increase of
geomagnetic activity” [124].
As a result, if MS is regarded a phenomenon related to
GMD, it not only can explain why MS or reports of clin-
ical manifestations resembling MS were rare in 19th cen-
tury and in medicine history of all previous centuries [7],
but also it can clarify why MS incidence and prevalence
have raised during 20th century.indicates to the solar cycle number. Reproduced by the kind
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1937 solar maximums started an increasing trend,
reached to mean yearly sunspot number of 151 in 1947
and then registered a record in 1957. It was followed by
a decrease in maximum sunspot number in the next
cycle (20th cycle), but backed to more than 150 spots in
the maximums of the following cycles. Figure 2 shows
that from 1933 to 1964, cycle average frequency of oc-
currence of Kp = 3 as well as other Kp situations had an
increasing trend. Among 1944 to 1955, the average
occurrences of Kp = 3 situation increased considerably
and reached to its maximum by 1960. As mentioned, in
Kp= 3 situation the edge of auroral oval is located over
geomagnetic ~60° latitude, therefore, the disturbances in
ground level magnetic field could be the cause of the in-
crease in MS incidence and prevalence in the areas
under and near to this line, relative to their angular dis-
tance to it. Regarding to these facts, GMD hypothesis
has the potential ability to explain why MS incidence
and prevalence in high latitudes increased from 1945–54
and dramatically by 1960. It also can be seen that aver-
age frequency of occurrences of Kp = 7 situation, that
occurs in severe geomagnetic storms, increased about
2.3 folds in 1955–64 in comparison to 1933–44. Such
severe storms not only expand the edge of auroral oval
to about geomagnetic 50° latitude, equal to geographic
55° latitude in central Europe and to geographic 40° lati-
tude in north America, but also cause global GMD that
can explain why MS incidence and prevalence started to
increase globally after 1960.
In both Figures 4 and 2, we can see that in 1965-76
(cycle 20), solar activity and frequency of all levels of
GMD decreased temporarily. It can explain why MS in-
cidence decreased in higher latitudes at this period.Gradual attenuation of latitudinal gradient of MS
In recent decades, increasing prevalence of MS in some
low latitude areas like Italy, against the expected north–
south gradient of MS [75,76], led to attenuation of
previously prominent latitudinal gradient of MS [3]. An
interesting finding about centennial increase of GMD
can describe the reason. However centennial increase of
GMD has had a latitudinal dependent nature and higher
latitudes has experienced the largest disturbances be-
cause of proximity to auroral oval, long term studies
have revealed surprisingly that the absolute amount of
centennial increase of GMD in low-latitudes has been
larger than mid-latitudes [124]. By this fact, it should
not be surprising that the rate of MS prevalence rising
in susceptible individuals of low-latitudes becomes even
larger than individuals of mid-latitudes over the time,
and consequently the prominent latitudinal gradient
attenuates gradually.The effect of month of birth
According to the result of two large epidemiological
studies, the risk of MS has associated to the month of
birth. Birth in May for inhabitants of north hemisphere
and November for south hemisphere have significantly
related to higher risk of MS in adulthood [126,127].
Previously, it has been tried to explain this feature by
means of maternal exposure to ultraviolet in the first tri-
mester [127]. As CNS myelination occurs mainly in the
third trimester, mostly from 29–39 gestational weeks
[128,129], it seems more reasonable that the mysterious
environmental factor should be related to this time.
Consequently, for individuals born in May and Novem-
ber, the environmental factor that may be related to
myelination time should occur at about mid-March and
mid-September, respectively.
However it is very complicated and is far beyond the
scope of this article, but it is well established that there
are semiannual increases in GMD which take place near
the time of equinoxes. In March, the earth reaches to
the highest southern solar latitudes, in the region that is
exposed to the fast solar winds [130]. At this time, how-
ever both hemispheres are affected, negative interplanet-
ary magnetic field Bx component and positive dipole tilt
of the earth cause favorable situation for northern hemi-
sphere high latitude reconnection phenomenon that leads
to accentuation of transpolar arcs and magnetic field
disturbances predominantly in auroral oval of northern
hemisphere [131]. In September, the situation is vice
versa and reconnection phenomenon is facilitated in the
southern hemisphere high latitudes [131]. If we assume
that GMD can increase the risk of MS by affecting adap-
tive cell immunity and causing memory T-cells that will
be activated in the future when identical temporary
changes occur due to magnetic field disturbances, there-
fore, it could be hypothesized that genetically vulnerable
individuals who were exposed to more GMD during
their CNS myelination process, when various antigens of
myelin structures are exposed and are prone to be
recognized by immunity, will have increased risk for
developing MS in the future. By this manner, GMD hy-
pothesis not only can efficiently explain the relation of
month of birth with the risk of MS, but also can describe
why immigrants born in high-risk area mostly preserve
the risk of their birthplace when immigrate to low-risk
places. In the other hand, we hypothesize that genetically
susceptible immigrants from low-risk to high-risk areas,
however experience lower exposures in their fetal period
that result in lower likelihood of production of memory
T-cells against myelin structures, but will show increased
MS risk [2] in their new residence area due to greater
frequency of exposure to GMD that will increase the
chance of being exposed to a matched GMD with their
memory T-cells sensitivity.
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birth month on MS risk would be conducted in mid to
low latitude geomagnetic areas, we would see the in-
creasing risk attributed to both equinox time of spring
and autumn, because these locations experience approxi-
mately identical increase in geomagnetic disturbances at
these times.
MS epidemics
Kurtzke et al. reported evidences of four epidemics of
MS in small population of Faroe Islands during 1940–
1991 [132]. They tried to explain these epidemics by de-
fining a hypothetical pathogen, possibly introduced by
British troops in 1945 [132]. Nevertheless, such a patho-
gen has not been found [2].
Considering the fact that solar magnetic activities and
related GMDs during 20th solar cycle were significantly
lesser than previous and next cycles, and as a conse-
quence assuming that they were not strong enough to
cause MS in susceptible Faroese, we can hypothesize
that what were seen in limited population of Faroe as
separated MS epidemics, were reflections of solar mag-
netic activities and their related geomagnetic conse-
quences on vulnerable individuals during 17th, 18th, 19th
and 21st solar cycles. Albeit this statement needs to be
tested by exact superposed epoch analysis of solar mag-
netic activities, GMDs and MS incidence in Faroe during
mentioned period.
Comparison with vitamin D hypothesis (VDH)
Finally and as a comparison, VDH has important weak-
nesses. We mentioned before that VDH cannot describe
the cause of parabolic prevalence of MS. In fact, the re-
lationship between the amount of solar ultraviolet B
(UVB) penetration and latitude are complex, due to
some factors such as differences in the thickness of at-
mosphere, cloud coverage and ozone cover situation. A
recent modeling study has shown that the notion of lati-
tudinal gradient of vitamin D levels in population is not
accurate [133,134]. Accordingly, geophysical studies has
confirmed that the amount of received UVB in a high
latitude area like Canada, over 24 h during summer
times, equals or even surpasses the received UVB at the
equator [133].
In the other hand, VDH cannot explain chronobiologi-
cal changes in MS incidence and prevalence. We know
that vitamin D related rickets was endemic in many
areas such as England in mid-17th centuries. It was a
common problem up to 1930 when finally by finding the
cause and using cod liver oil and enough sun exposure,
medicine overcame the disease [135]. Therefore, if MS
actually is related to vitamin D deficiency, it is reason-
able that we had records of more incidence and preva-
lence of MS or reported clinical manifestation thatresembling MS before 1930. We know that it is in con-
trast with what has happened during history of MS. Eco-
logical and genetic studies did not support the
significant association between serum vitamin D level
and MS, and observational studies did not find strong
direct evidences of vitamin D effects on MS incidence
[133]. Moreover, VDH cannot exactly illuminate the
cause of recent attenuation of latitudinal gradient of
MS prevalence and some phenomenon like MS
epidemics [4].
Magnetic resonance imaging (MRI): should we be
concerned about it?
Nowadays MRI is the mainstay of diagnosis and follow-
up of MS patients. During preparation of this manu-
script and regarding used facts and mechanisms to
construct and describe our hypothesis, we realized that
the presence of the words “magnetic” and “resonance” in
the name of MRI will inevitably evoke questions about
its safety for MS patients. Authors, as designers of GMD
hypothesis, cannot answer such questions definitely at
present time. The main cause of uncertainty in this issue
originates from the fact that we are not aware about the
exact mechanism that GMD or other magnetic fields
may probably elicit an immune response in CNS. Un-
doubtedly, the answer to this matter is completely
dependent to the mechanism of such effect. For ex-
ample, if future studies confirm that GMD may elicit im-
mune response in human body mainly by changing
lymphocyte Ca+2, as was described in introduction and
subsection of “the hypothesis”, then with a high prob-
ability, at least in the case of inducing cyclotron reson-
ance in Ca2+, we should not be concerned about MRI.
However MRI works by inducing cyclotron resonance,
but the target of this technic is hydrogen nucleus. It is a
physical fact that resonant frequency of atomic nucleus
of any element is different from others and is related to
its electric charge, atomic mass and albeit the strength
of exerted magnetic field. In quantum mechanics, this
resonant frequency can be calculated by means of Lar-
mor equation. The Larmor equation is ω0 = yB0. Where
ω0 is the resonant frequency, y is a unique constant for
any element that is called gyromagnetic ratio and B0 is
the strength of external magnetic field. Gyromagnetic
ratio of hydrogen is 42.58 mega Hertz per Tesla (MHz/
T), while this ratio is 2.86 MHz/T for calcium. Therefore,
in magnetic fields of clinical MRI, i.e. 1.5 and 3 Tesla,
resonant frequencies of hydrogen are about 63 and 127
MHz, respectively. While these frequencies for calcium is
about 4 and 8 MHz, respectively. As clinical MRI appli-
ances use pulse frequencies of 60 MHz up to 128 MHz
[136], their pulse frequencies are not match with calcium
nucleus to elicit cyclotron resonance in them. It is the
physical basis of a known fact in clinical practice that
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tissues or bony structures.
In contrast, if future studies confirm GMD hypothesis
and show that the mechanism of GMD effects is related
to its impact on brain magnetosomes and their magnet-
ite contents, that physically are sensitive to magnetic
fields, then the safety of MRI for MS patients should ne-
cessarily be revaluated regarding to this matter.
In conclusion, the recommendation of authors at
present time is to use MRI only for evaluating the pres-
ence of demyelinating lesions at the first attack or even-
tually for confirmation of dissemination of lesions in
time for necessary cases, and then to follow-up MS pa-
tient clinically and to avoid ordering repeated MRI for
this aim as far as possible.
Limitations
However ecological study is a very suitable and inexpen-
sive way for hypothesis evaluation in large scale and in
population level, but it should be reminded that such
studies are subject to be impressed by ecological fallacy.
In the time of interpretation of the result, it should be
noted that findings related to aggregate population may
not always be applicable to individuals.
Other limitation of the study is its limitation in regard-
ing the exact amount and time of exposure of popula-
tion to GMD. Geomagnetic coordinates and experienced
GMD of any locations change over time. However we
determined AMAG60 of any location in the nearest time
of its MS prevalence study and considered it as a vari-
able related to the amount of experienced GMD by
population, but we did not know the actual time in the
life that experiencing GMD may affect individual suscep-
tible for MS. It may be during fetal time, neonatal
period, childhood or adulthood.
Nevertheless we provided evidences of how GMD pos-
sibly can provide essential components for causing MS,
but it should be noticed that all of these evidences are
from in vitro studies. In the other hand, however we
assumed that there may be a genetical basis that can be
the cause of sensitivity of susceptible individuals to
GMD, such a genetic basis, except than a new finding
about human cryptochrome CRY2 gene [137], was not
confirmed or evaluated up to now.
Another important limitation of GMD hypothesis, at
least at present time, is related to the issues of difference
among sexes in the case of MS incidence and preva-
lence, and other related factors such as the effect of
pregnancy or post-partum period on alteration of MS
attacks. The main cause of inability of GMD hypothesis
to provide a reasonable description about these issues
originates from the lack of information about the exact
mechanism of the effect of GMD. There are evidences
that hormones, for example melatonin, may have a rolein the response of brain to GMD [137]. But, we could
not find such studies about sexual hormones. Therefore,
providing probable explanations about these phenomena
is dependent to future studies in this field.
Conclusions
We described how GMD can explain main issues about
MS. GMD hypothesis not only has the ability to provide
possible explanation about MS in cellular level, but also
has the ability to clarify the cause of relapsing-remitting
nature, chronobiology, latitudinal prevalence, alterations
in MS distribution and some phenomenon like the birth
month effect and MS epidemics. It also can solve the
puzzle of longstanding failure of finding the mysterious
environmental cause of MS by biochemical marker
dependent technics and give us the chance to make
some general prediction about the disease activity, be-
cause space-weather situations and GMDs are relatively
predictable.
It was just a preliminary evaluation of this hypothesis
with limitation related to ecological study. At this time
the main shortcoming of GMD hypothesis is the lack of
direct evidences. Regarding to the provided answers by
GMD for important issues of MS, we believe that our
hypothesis deserves to be considered for further individ-
ual based validation studies. Like other scientific hypoth-
esis, there is the possibility that future studies do not
confirm GMD hypothesis. Nonetheless, the importance
of GM60L should not be neglected and other possible
environmental factors that may be related to this line
and MS should be evaluated.
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